Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0080878 |
| Name | IDH-wildtype glioblastoma |
| Definition | A glioblastoma that is characterized by high cellularity, high mitotic activity, necrosis or microvascular proliferation and that lacks mutations in IDH genes. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma malignant astrocytoma glioblastoma IDH-wildtype glioblastoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| BRAF V600E | Vemurafenib | IDH-wildtype glioblastoma | predicted - sensitive | detail... |
| BRAF V600E | Dabrafenib + Trametinib | IDH-wildtype glioblastoma | predicted - sensitive | detail... |
| IDH1 wild-type | N/A | IDH-wildtype glioblastoma | not applicable | detail... |
| IDH2 wild-type | N/A | IDH-wildtype glioblastoma | not applicable | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03158389 | Phase Ib/II | Vismodegib Alectinib Idasanutlin Temsirolimus Atezolizumab Palbociclib APG101 | NCT Neuro Master Match - N²M² (NOA-20) (N²M²) | Completed | DEU | 0 |
| NCT03970447 | Phase II | VAL-083 ADI-PEG 20 AZD1390 VT1021 Lomustine Regorafenib Temozolomide GDC-0084 | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE) | Recruiting | USA | FRA | DEU | CHE | CAN | AUS | 0 |
| NCT04197934 | Phase I | WSD0922 | WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer with Central Nervous System Metastases | Recruiting | USA | 0 |
| NCT04559230 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan in Recurrent Glioblastoma | Recruiting | USA | 0 |
| NCT04910022 | Phase Ib/II | NMS-03305293 + Temozolomide Lomustine | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | Active, not recruiting | USA | NLD | ITA | CHE | 1 |
| NCT04945148 | Phase II | Metformin + Temozolomide | Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide (OPTIMUM) | Recruiting | ITA | FRA | 0 |
| NCT05168423 | Phase I | CART-EGFR-IL13Ra2 cells | CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM | Active, not recruiting | USA | 0 |
| NCT05267106 | Phase II | Pemigatinib | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | Terminated | USA | NLD | ITA | GBR | FRA | ESP | DNK | DEU | 1 |
| NCT05326464 | Phase III | Tofacitinib | Tofacitinib in Recurrent GBM Patients | Active, not recruiting | USA | 0 |
| NCT05432375 | Phase I | Tinostamustine | Study of Tinostamustine for Adjuvant Treatment of Glioblastoma | Active, not recruiting | ESP | CHE | 0 |
| NCT05432518 | Phase I | Olaparib Palbociclib Afatinib Everolimus Dasatinib | GBM Personalized Trial | Recruiting | CAN | 0 |
| NCT05463848 | Phase II | Olaparib + Pembrolizumab + Temozolomide Pembrolizumab | Surgical Pembro +/- Olaparib W TMZ for RGBM | Recruiting | USA | 0 |
| NCT05465954 | Phase II | NT-I7 + Pembrolizumab | Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma | Recruiting | USA | 0 |
| NCT05474378 | Phase I | Retroviral vector transduced B7-H3 CAR T cells | B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme | Recruiting | USA | 0 |
| NCT05629702 | Phase II | Nabiximols + Temozolomide Temozolomide | ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids (ARISTOCRAT) | Recruiting | GBR | 0 |
| NCT05734560 | Phase Ib/II | 2141 V-11 + D2C7-IT | D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients | Recruiting | USA | 0 |
| NCT05765812 | Phase Ib/II | Debio 0123 + Temozolomide | A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma | Recruiting | USA | ESP | CHE | 0 |
| NCT05879250 | Phase II | WP1066 | WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | Active, not recruiting | USA | 0 |
| NCT05917145 | Phase I | WSD-0628 | ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma | Recruiting | USA | 0 |
| NCT05986851 | Phase II | Azeliragon | Azeliragon in MGMT Unmethylated Glioblastoma | Active, not recruiting | USA | 0 |
| NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |
| NCT06061809 | Phase II | Bevacizumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Bevacizumab + Nogapendekin alfa inbakicept | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | Recruiting | USA | 0 |
| NCT06069726 | Phase II | Atezolizumab | A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial (MOAB) | Recruiting | USA | 0 |
| NCT06095375 | Phase I | Regorafenib + Temozolomide | Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients (REGOMA-2) | Active, not recruiting | ITA | 0 |
| NCT06097975 | Phase I | Ipilimumab + Nivolumab | A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma (NEO-GLITIPNI) | Recruiting | BEL | 0 |
| NCT06188702 | Phase Ib/II | S095035 S095035 + TNG462 | S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP | Recruiting | USA | ITA | FRA | ESP | DNK | DEU | AUS | 1 |
| NCT06258018 | Phase Ib/II | Niraparib + Temozolomide | Niraparib and Temozolomide in Patients Glioblastoma (ONC-2022-001) | Not yet recruiting | ITA | 0 |
| NCT06297512 | Phase II | Doxorubicin + Temozolomide | Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). | Recruiting | ITA | 0 |
| NCT06410248 | Phase I | Temozolomide + Triapine Triapine | Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma | Recruiting | USA | 0 |
| NCT06504381 | Phase Ib/II | Toca FC + Vocimagene amiretrorepvec Temozolomide + Toca FC + Vocimagene amiretrorepvec | DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | Recruiting | USA | 0 |
| NCT06552260 | Phase I | Trigriluzole | A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma | Recruiting | USA | 0 |
| NCT06630260 | Phase Ib/II | Defactinib + RO5126766 + Temozolomide Defactinib + RO5126766 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours (5G-RUBY) | Recruiting | GBR | 0 |
| NCT06632236 | Phase I | Amivantamab-vmjw | 5G-EMERALD: Amivantamab in Malignant Brain Tumours (5G-EMERALD) | Recruiting | GBR | 0 |
| NCT06641908 | Phase I | M3554 | Anti-GD2 ADC M3554 in Advanced Solid Tumors | Recruiting | USA | GBR | FRA | CHE | BEL | 1 |
| NCT06650605 | Phase I | 123I-ATT001 | Phase 1 Open-label Study of 123I-ATT001 in Subjects with Relapsed Glioblastoma (CITADEL-123) | Recruiting | GBR | 0 |
| NCT06672575 | Phase Ib/II | Ivonescimab | A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma | Recruiting | USA | 0 |
| NCT06805305 | Phase II | Temozolomide DOC1021 + Temozolomide | DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) | Recruiting | USA | 0 |
| NCT06810544 | Phase Ib/II | Abemaciclib + TNG456 TNG456 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | Recruiting | USA | 0 |
| NCT06824662 | Phase I | Quisinostat | Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas | Recruiting | USA | 0 |
| NCT06831526 | Phase I | Azeliragon + Temozolomide | Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma | Recruiting | USA | 0 |
| NCT06894979 | Phase I | AZD1390 | Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma | Recruiting | USA | 0 |
| NCT06896110 | Phase I | Azacitidine + Nivolumab | Intrathecal Azacitidine and Nivolumab in Patients with Recurrent High-grade Glioma | Enrolling by invitation | USA | 0 |
| NCT06934889 | Phase I | ABBV-637 + ERAS-801 ABBV-637 + Temozolomide ERAS-801 + Mirzotamab clezutoclax Mirzotamab clezutoclax + Temozolomide | Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma | Recruiting | USA | 0 |
| NCT06973096 | Phase I | CART-EGFR-IL13Ra2 cells | CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy | Recruiting | USA | 0 |
| NCT06991101 | Phase II | Ruxolitinib + Temozolomide Temozolomide | Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma | Not yet recruiting | USA | 0 |
| NCT07089641 | Phase I | ERAS-801 | ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial (ERAS801-SARG) | Recruiting | USA | 0 |
| NCT07100730 | Phase III | 131I-TLX-101 + Lomustine 131I-TLX-101 | Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma (IPAX BrIGHT) | Recruiting | AUS | 0 |
| NCT07185880 | Phase I | MT-125 | A Phase 1 Study of the Safety and Tolerability of MT-125 in GBM Patients (STAR-GBM) | Not yet recruiting | USA | 0 |
| NCT07209241 | Phase I | CART-EGFR-IL13Ra2 cells | Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM | Recruiting | USA | 0 |
| NCT07223034 | Phase I | lutetium Lu 177 vipivotide tetraxetan + Temozolomide | A Study of 177Lu-PSMA-617 in People With Gliomas | Recruiting | USA | 0 |